1	Restoration of leukomonocyte counts is associated with viral
2	clearance in COVID-19 hospitalized patients
3	
4	Xiaoping Chen ¹ , Jiaxin Ling ² , Pingzheng Mo ¹ , Yongxi Zhang ¹ , Qunqun
5	Jiang ¹ , Zhiyong Ma ¹ , Qian Cao ¹ , Wenjia Hu ¹ , Shi Zou ¹ , Liangjun Chen ³ ,
6	Lei Yao ⁴ , Mingqi Luo ¹ , Tielong Chen ¹ , Liping Deng ¹ , Ke Liang ¹ , Shihui
7	Song ¹ , Rongrong Yang ¹ , Ruiying Zheng ¹ , Shicheng Gao ¹ , Xien Gui ¹ ,
8	Hengning Ke ¹ , Wei Hou ⁴ , Åke Lundkvist ² , Yong Xiong ¹
9	
10	¹ Department of Infectious Diseases, Zhongnan Hospital of Wuhan
11	University, No.169, Donghu Road, Wuchang District, 430071 Wuhan,
12	Hubei Province, China
13	² Department of Medical Biochemistry and Microbiology, Zoonosis
14	Science Center, University of Uppsala, Uppsala, Sweden
15	³ Department of Laboratory Medicine, Zhongnan Hospital of Wuhan
16	University, Wuhan, People's Republic of China
17	⁴ State Key Laboratory of Virology/ Institute of Medical Virology/ Hubei
18	Province Key Laboratory of Allergy and Immunology, School of Basic
19	Medical Sciences, Wuhan University, 185 Donghu Road, Wuhan 430071,
20	Hubei Province, China

23	Correspo	nding	to:
----	----------	-------	-----

- 24 Xiaoping Chen, MD & PhD
- 25 E-mail address; alackcn@126.com
- 26 Tel: 86-27-67812880
- 27 Address: Department of infectious diseases, Zhongnan Hospital of
- 28 Wuhan University, No.169, Donghu Road, Wuchang District, Wuhan
- 29 City, Hubei Province, P.R China.
- 30
- 31 Yong Xiong, MD & PhD
- 32 E-mail address; yongxiong64@163.com
- 33 Tel: 86-27-67812880
- Address: Department of infectious diseases, Zhongnan Hospital of
 Wuhan University, No.169, Donghu Road, Wuchang District, Wuhan
- 36 City, Hubei Province, P.R China.
- 37

39 Summary

Background: Viral clearance is one important indicator for the recovery
of SARS-CoV-2 infected patients. Previous studies have pointed out that
suboptimal T and B cell responses can delay viral clearance in MERSCoV and SARS-CoV infected patients. The role of leukomonocytes in
viral clearance of COVID-19 patients is not yet well defined.

45 *Methods:* From January 26 to February 28, 2020, an observational study was launched at the Department of Infectious Diseases, Zhongnan 46 47 Hospital of Wuhan University, Wuhan, China. We enrolled 25 48 laboratory-confirmed COVID-19 patients, whose throat-swab specimens 49 were tested positive for SARS-CoV-2 infection by qRT-PCR. To 50 investigate the factors that contribute to the viral clearance, we 51 comprehensively analyzed clinical records, counts of lymphocyte subsets 52 including CD3+, CD4+, CD8+ T cells, B cells and NK cells in the 53 patients who successfully cleared SARS-CoV-2, and compared to those 54 that failed to, after a standardized treatment of 8-14 days.

Findings: In 25 enrolled COVID-19 patients, lymphopenia was a
common feature. After the treatment, 14 out of the 25 enrolled patients
were tested negative for SARS-CoV-2. The patients that cleared the
infection had restored the numbers of CD3+, CD4+, CD8+ T cells and B

59	cells as	compared	to th	e still	viral	RNA	positive	patients,	while	the
60	recovere	d patients h	nad a I	nigher	count	of leul	comonocy	ytes.		

61	Conclusions: By comparison of leukomonocytes counts in COVID-19
62	patients at different stages of the disease, we found that CD3+, CD4+,
63	CD8+ T cells and B cells appear to play important roles in viral clearance.
64	The restoration of leukomonocytes counts from peripheral blood can be
65	used as prognosis for the recovery of an COVID-19 infection. We
66	propose that restoration of leukomonocytes counts can be added to the
67	COVID-19 diagnostic guidance as a criterion for releasing and
68	discharging patients.

69 Keywords. COVID-19; SARS-CoV-2, leukomonocytes; viral clearance.

70 Funding

71 This study was funded by the Zhongnan Hospital of Wuhan University

72 Science, Technology and Innovation Seed Fund, grant number

73 znpy2018007 and the Swedish Research Council, grant number 2017-

74 05807. The funders had no role in study design, data collection or

analysis, decision to publish or preparation of the manuscript. The authors

76 declared no competing interests.

77 Introduction

In December 2019, a cluster of novel coronavirus-associated pneumonia 78 79 cases was emerging in Wuhan, China [1]. The disease rapidly spread from Wuhan and caused a wide epidemic in China. The World Health 80 81 Organization (WHO) has recently named the disease as Coronavirus Disease-2019 (COVID-19) [2]. The etiology of the disease is a novel β -82 83 coronavirus, taxonomically named as severe acute respiratory syndrome 84 coronavirus 2 (SARS-CoV-2). Until February 29, 2020, SARS-CoV-2 85 causes an epidemic worldwide. More than 80,000 people in over 60 86 countries or territories have been contracted of COVID-19, and more 87 than 3000 people have died [3].

The clinical manifestations of COVID-19 cases range from an asymptomatic course to serve acute respiratory symptoms and even acute respiratory failure [4-7]. Transmission occurs from human to human with nosocomial transmissions. The incubation time of COVID-19 has been reported from 0 to 24 days and also asymptomatic carriers can be infectious [8].

As a zoonotic virus, the natural host of SARS-CoV-2 is believed to be
bats [9], however, the process of cross-species transmission(s) is still not
known. The very first cases were associated with the Huanan Seafood
Wholesale Market in Wuhan, China [10]. There is no effective antiviral

98 drug available yet. Although the pathogenesis of COVID-19 is still 99 unclear, lymphopenia has been found in most COVID-19 patients [10-12]. 100 This feature has also been found in the other two fatal human coronavirus 101 infections caused by severe acute respiratory syndrome coronavirus 102 (SARS-CoV) and the Middle East respiratory syndrome coronavirus 103 (MERS-CoV) [13, 14]. Previous studies showed that T cells, especially 104 CD4+ and CD8+ T cells, play a significant antiviral role in balancing the 105 combat against MERS-CoV or SARS-CoV infections [15]. These results 106 suggested that leukomonocytes counts could be critical indicators 107 associated with severity and the disease outcome. In this study, we 108 retrospectively analyzed 25 COVID-19 cases to elucidate the dynamic of 109 lymphocyte subset changes in the peripheral blood and their roles during 110 the viral clearance.

111

112 Methods

113 *Study design*

From January 26 to February 28, 2020, 25 COVID-19 patients who had
been repeatedly analyzed for lymphocyte subsets and SARS-CoV-2 RNA
were enrolled in the study. Informed consents were obtained from all

patients upon admission to the Department of Infectious Diseases,Zhongnan Hospital of Wuhan University, Wuhan, China.

119

120 *Data collection*

121 The medical records, including epidemiological and demographic 122 information, clinical manifestations, laboratory data, and outcome of 123 disease, were collected. To avoid subjective biases, two investigators 124 reviewed the data independently and made a final consensus.

Peripheral blood (100 μ l) was collected from patients at admission to hospital and after 7 – 10 days of standard therapy (Version 6, 2020 Feb 127 18,

128 http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351

d7da8aefc2.shtml). Lymphocyte subsets such as CD3+, CD4+, CD8+ T
cells, B cells and NK cells were stained by using the BD MultitestTM IMK
kit (BD Ltd., San Jose, CA, USA) according to the manufacturer's
instruction. The lymphocyte subset analyses were performed by flow
cytometry (BD FACSCantoTM II Flow Cytometer).

Serial throat-swab samples were taken from patients at the admission to
hospital during 8 – 14 days of standardized treatment (see Table 1)
according to the recommendation in the guideline. The swab samples

137 were placed in 150 µL of virus preservation solution and viral RNA 138 subsequently extracted as described earlier [5, 16]. Two target genes of the SARS-CoV-2 genome, including the open reading frame 1ab 139 140 (ORF1ab) and the nucleocapsid protein (N) gene, were simultaneously 141 amplified and tested in the real-time RT-PCR assay by using a SARS-142 CoV-2 nucleic acid detection kit according to the manufacturer's protocol 143 (Shanghai Bio-Germ Medical Technology Co Ltd, Shanghai, China). The 144 reaction mixture consisted of 12 μ L reaction buffer, 4 μ L of enzyme 145 solution, 3 µL of diethyl pyrocarbonate-treated water, 2 µL of RNA 146 template, and 4 µL of probe/primers solution, which contained two sets of 147 probe primers: one set targets towards to ORF1ab (forward prime 5'-148 CCCTGTGGGTTTTACACTTAA-3'; reverse primer 5'-149 ACGATTGTGCATCAGCTGA-3'; and the probe 5'-VIC-150 CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'), and another 151 targets towards to Ν (forward primer 5'-GGGGAACTTCTCCTGCTAGAAT-3'; 5'-152 primer reverse 153 CAGACATTTTGCTCTCAAGCTG-3'; and the probe 5'-FAM-154 TTGCTGCTGCTTGACAGATT-TAMRA-3').

The results of the real-time RT-PCR analyzes were interpreted as: a cycle threshold value (Ct-value) less than 37 was defined as a positive result; a Ct-value of 40 or more was defined as a negative result; a

158 medium load result, defined as a Ct-value of 37 to less than 40, required 159 another test for confirmation. The patients who repeatedly tested SARS-160 CoV-2 RNA negative for at least two times with an interval of more than 161 1 day were regarded as viral negative. These diagnostic criteria were 162 based on the recommendation by the National Institute for Viral Disease 163 Control and Prevention, China (http://ivdc.chinacdc.cn/gjhz/jldt/202002/P020200209712430623296.pdf). 164

165 Statistical analysis

We used the SPSS 17.0 software package for the statistical analyses. We used X^2 tests or Fisher's exact tests for categorical variables. For measurement of the data, a normal distribution was tested first and then proceeded to t-test, expressed as the mean \pm standard deviations; otherwise the Mann-Whitney U test was used for non-normal distribution data, expressed in terms of median (25%–75% interquartile range, IQR). A p value of < 0.05 was considered statistically significant.

173

174 The principle of medical ethics

175 This study was approved by the ethics board in Zhongnan Hospital of176 Wuhan University, Wuhan, China (No.2020011).

177

178 **Results**

179 Baseline Characteristics of COVID-19 patients

180 A total of 25 patients, 11 men and 14 women were enrolled in this study 181 (Table 1). The ages of the patients spanned from 25 to 80 years (average 182 51.4±16.6 years). Fourteen people described a previous exposure history 183 to the source of infection, either from the Huanan Seafood Wholesale 184 Market or through direct contacts with COVID-19 patients. The most 185 common symptoms at the onset of illness were: fatigue (80.0%), fever (37.4–39.1°C, 75.0%), myalgia (68.0%), cough (64.0%), and less 186 187 common: dyspnea (28.0%) and diarrhea (20.0%). Seven cases had 188 underlying diseases such as hypertension, cardiovascular disease, diabetes, malignancy or chronic liver disease (Table 1). 189

190 Laboratory analysis before and after treatment

191 Laboratory analysis were performed before the treatment. The biochemical included alanine 192 tests aminotransferase, aspartate 193 aminotransferase, aspartate aminotransferase, creatinine, and D-dimer, 194 which all were found normal (Table 2). However, blood counts of the patients showed leucopenia ($4.5\pm1.9 \times 10^9/L$) and lymphopenia (< 1.3) 195 $\times 10^{9}$ /L). The counts of CD3+ T cells, CD4+ T cells, CD8+ T cells, B 196 197 cells, and NK cells were found lower than normal values. Interleukin-6 had increased to a mean of 16.1 (3.7 - 31.4) pg/ml. Five patients had an increase of procalcitonin (≥ 0.05 ng/mL) (Table 2).

200 The treatment was mainly of supportive care (Table 1). Twenty-four 201 patients were given antiviral therapy including arbidol (orally, 200 mg, 202 three times per day), and oxygen support. Antibiotic therapy, both orally 203 and intravenous, were given as described in Table 1. Fourteen patients 204 received corticosteroids to suppress an excessive inflammatory activation. 205 After standardized treatment of 8–14 days, according to the laboratory 206 analysis of viral RNA, fourteen patients showed viral clearance and 11 207 patients were still positive for SARS-CoV-2 viral RNA (Table 1).

208 When comparing the group that showed viral clearance and the group that 209 failed, we found no significant association to sex, epidemiological 210 exposure history, comorbidities, onsets of signs and symptoms, or 211 treatment, but with the age and days of hospitalization. The mean days of 212 hospitalization in the group that showed viral clearance were 12 days 213 (10.0 - 15.0), which was shorter as compared to the group that failed to 214 clear the virus, for which the average days were 21 (18.0 - 23.0) days. 215 Age can play an important role during the viral clearance: patients 216 without viral clearance were older $(60.2\pm16.9, y)$ than patients with viral

217 clearance $(44.5 \pm 13.0 \text{ y})$, showing a statistically significant difference 218 (Table 1).

219 Association between peripheral lymphocyte counts and disease220 outcomes

221 Since lymphopenia was found in all the patients in the current study and 222 also earlier reported elsewhere [10], we further analyzed the association 223 between peripheral lymphocyte counts and disease outcomes. In the 14 224 patients with viral clearance after the 8 - 14 days of treatment, the counts 225 of CD3+ T cells, CD4+ T cells, CD8+ T cells, and B cells were restored 226 close to normal levels and with a significant difference as compared to 227 the counts at admission in 12 patients. In the remaining 2 patients with 228 viral clearance the leukomonocytes counts were still at low levels (Figure 229 1, A-E). However, in the patients without viral clearance (No.=11), no differences were seen before and after treatment regarding the CD3+, 230 231 CD4+, CD8+, B, and NK cell counts (Figure 1, F-J). The association 232 between peripheral lymphocyte counts and viral detection suggested that 233 higher counts of CD3+ T cells, CD4+ T cells, CD8+ T cells, and B cells 234 had a significant impact on the viral clearance.

236	To further monitor the disease outcome of those 11 patients who were
237	still positive for SARS-CoV-2 virus RNA, we extended the same
238	treatment to 15 – 23 days (Figure 2). At 15 –23 days, 7 patients were
239	negative for viral RNA detection (data for leukomonocyte subsets was
240	available for 6 of these 7 patients), but 4 patients were still positive (all
241	these four had been tested for leukomonocyte subsets). The 4 viral RNA
242	positive patients had low counts of CD3+ T cells (< 1200×10^{9} /L), CD4+
243	T cells (< 700 ×10 ⁹ /L), CD8+ T cells (< 500 ×10 ⁹ /L), B cells (< 400
244	$\times 10^9/L)$, and NK cells (< 400 $\times 10^9/L)$. Due to the small sample size, no
245	statistically significant differences for the cell counts were observed,
246	except for the NK cell counts, which showed a significant decrease in the
247	4 viral RNA positive patients (Figure 2, J). However, we found a similar
248	trend that the increased counts of CD3+ T cells and CD8+ T cells
249	corresponded to cases which were negative for viral RNA detection (5
250	out of 6). One case that still had low counts of CD3+ T cells, CD4+ T
251	cells, CD8+ T cells, B cells and NK cells was found negative for viral
252	RNA.

254 Clinical outcome

We observed the clinical course of 25 COVID-19 patients within 23 days
of treatment. During the first phase of treatment, at 8 – 14 days, fourteen

257 patients showed viral clearance and 12 of them were discharged from the 258 hospital according to the guideline. The treatment of oxygen support 259 therapy and clinical observation was continued for the remaining 2 260 patients in this group. Eleven viral RNA positive patients received a 261 second phase of treatment between 15–23 days. Until February 28, 7 of 262 these 11 patients turned out to be viral RNA negative. Four of these 7 263 patients were then discharged from the hospital, while the other 3 (one 264 had a liver disease and the other two still had significant clinical symptoms), together with the 4 patients who were still positive for viral 265 266 RNA, were kept under treatment (Table 1). In total, 9 out of the 25 267 COVID-19 patients were still hospitalized after 23 days of clinical 268 treatment.

269

270 **DISCUSSION**

In this report, we retrospectively investigated the changes of CD3+, CD4+, CD8+, B, and NK cell counts in peripheral blood of 25 COVIDpatients during the viral infection and the mechanisms for viral clearance. We found that restoration of CD3+, CD4+, CD8+ T cells, B cells and NK cells was associated the viral clearance in COVID-19 patients. According to the Guideline of the treatment of COVID-19 (Version 6,

278 2020

http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351 279 d7da8aefc2.shtml), the diagnosis of COVID-19 infection is based on an 280 281 epidemiological history of contact with COVID-19 patients or travel to 282 endemic areas, combined with laboratory testing including viral RNA 283 detection and radiological findings. COVID-19 patients have similarities 284 of the clinical features with other coronavirus infections. Most patients 285 had fever, cough, myalgia and fatigue, and less often showed symptoms of dyspnoea, haemoptysis and diarrhea [10]. Half of the cases had 286 287 comorbidities such as diabetic, hypertension and cardiovascular diseases 288 [10]. In our study, we also found some cases that had underlying diseases 289 but without any association with the disease outcome. Age is a risk factor 290 for a more severe disease outcome, because of the generally inferior function of the immune system among older people. Based on the 291 292 guideline, the patients who have normal body temperature for more than 293 three days, mitigation of respiratory symptoms, improvement of radiological evidences for lesions, and had been tested negative for 294 295 specific SARS-CoV-2 RT-PCR at least twice, can be discharged from the 296 hospital. The average hospitalized time was 17 days (IQR 11.5 - 21.5), 297 and even as long as 23 days for the patients that were released from our 298 study [5], suggesting the time for SARS-CoV-2 clearance is also around

15

18.

17 days or longer. This was also been observed in an earlier study where
the shedding of SARS-CoV-2 in saliva continued up to 11 days [17].

301 Until now, there is no effective antivirals available against SARS-CoV-2. To eliminate the virus an effective immunological response with a 302 303 minimum of immunopathological effects is required [18]. The antigen 304 presentation requires inhibitory alveolar macrophages and dendritic cells 305 (DCs). Successful stimulation can produce viral specific CD4 T cells, 306 which are involved in the development of a specific humoral response, 307 including neutralizing antibodies that can block the viral entry to the cells 308 [19]. CD8+ cytotoxic T cells are required for recognition and killing of 309 the infected cells, further playing a crucial role in SARS-CoV clearance 310 [20, 21]. However, in the biopsy samples from the patients who died of 311 COVID-19, histological examination showed pulmonary oedema with 312 hyaline membrane formation, and interstitial mononuclear inflammatory 313 infiltrates in the lung tissue, suggesting that acute respiratory failure was 314 the cause of death, underlying mechanism that an over-activated 315 immunity injured the lung tissue [12]. Among SARS patients, high 316 expression of dysregulated chemokines and cytokines were found in 317 blood and lungs [22], due to the reason of aberrant immune response 318 caused by the viruses [13, 14]. The delayed or suboptimal immune 319 responses would make chances for SARS-CoV and MERS-CoV to

320 escape from the immune responses, and survive and replicate in the host 321 cells, leading a further delay of the viral clearance [15, 23]. In our study, COVID-19 patients at older ages needed a longer time for the recovery, 322 323 likely due to the fact that aging is associated with a set of functional and 324 structural alterations in the immune system [24]. Immune-modulators, as 325 corticosteroids, have been empirically used in both SARS and COVID-19 326 patients [10, 25]. Since corticosteroids might have a decline effect of 327 circulating specific B and T cell subsets [26], the usage on COVID-19 patients should be carefully evaluated before considered [12, 27]. 328

329 A rapid and generalized lymphopenia has been observed as a prominent 330 part in SARS-CoV and MERS infections [28]. Lymphopenia has also 331 been observed in other viral infections such as measles virus and avian 332 influenza virus, swine foot-and-mouth disease virus, respiratory syncytial 333 virus, and HIV [29-33]. The possible reasons would be lymphocyte 334 sequestration in the lung tissues, or immune-mediate lymphocyte 335 destruction. In MERS infections, the function of bone marrow or thymus suppressed, and furthermore, T cells underwent apoptosis [34-36]. In 336 COVID-19 patients, peripheral CD4 and CD8 T cell counts were found 337 338 decreased but, they were also hyperactivated, which could result in severe 339 immune injuries [12].

340	In the present study, we followed the current guidelines and used a
341	specific SARS-CoV-2 realtime RT-PCR for viral detection. Surprisingly,
342	one lymphopenia patient (37y, male, chronic liver disease) was found
343	negative by the realtime RT-PCR and his symptoms had been improved
344	but he is still in hospital. Until now, specific viral RNA detection based
345	on realtime RT-PCR is commonly used in the clinical diagnosis. The
346	usage of realtime RT-PCR is versatile in the detection of SARS-CoV-2 in
347	the respiratory tract specimen or throat swab, but we must keep in mind
348	that those methods always are followed by the probability of false
349	positive/negative. Besides, around 14% of the discharged COVID-19
350	patients were tested as positive again on follow up samples
350 351	patients were tested as positive again on follow up samples (https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19-
351	(https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19-
351 352	(https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19- patients-in-guangdong-tested-positive-again-101520415.html), showing
351 352 353	(https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19- patients-in-guangdong-tested-positive-again-101520415.html), showing the recurrence of SARS-CoV-2. This imply that viral detection cannot be
351 352 353 354	(https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19- patients-in-guangdong-tested-positive-again-101520415.html), showing the recurrence of SARS-CoV-2. This imply that viral detection cannot be used as a single criterion for COVID-19 diagnosis. As a highly
351 352 353 354 355	(https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19- patients-in-guangdong-tested-positive-again-101520415.html), showing the recurrence of SARS-CoV-2. This imply that viral detection cannot be used as a single criterion for COVID-19 diagnosis. As a highly contiguous disease with a fatality of approximately 2.3% and up to 49.0%
351 352 353 354 355 356	(https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19- patients-in-guangdong-tested-positive-again-101520415.html), showing the recurrence of SARS-CoV-2. This imply that viral detection cannot be used as a single criterion for COVID-19 diagnosis. As a highly contiguous disease with a fatality of approximately 2.3% and up to 49.0% in critical cases [7], every hospitalized COVID-19 patient must be

360	In conclusion, we retrospectively analyzed 25 COVID-19 cases and
361	found that restoration of peripheral leukomonocytes could help the
362	clearance of SARS-CoV-2. We propose here that leukomonocytes counts
363	may serve as a valid prognosis of immune reconstitution for recovery of
364	COVID-19 infection and that can update the current COVID-19 diagnosis
365	guideline.

367 Acknowledgement

368 An especially strong appreciation goes to all the clinical physicians,

369 health caregivers, clinical laboratory personals, epidemiologists, and

370 researchers who have been fighting against the SARS-CoV-2 epidemic.

- 371 We also acknowledge the supports from both nationwide and
- 372 international resources.
- 373

374 **Reference**

375 376	1.	Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020 .
377	2.	Naming the coronavirus disease (COVID-2019) and the virus that causes it.
378		Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-
379		2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-
380		the-virus-that-causes-it.
381	3.	Available at: <u>https://promedmail.org/</u> .
382	4.	Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in
383		patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63
384		patients in Wuhan, China. Eur Radiol 2020 .
385	5.	Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized
386		Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
387		JAMA 2020 .
388	6.	Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with
389		Pneumonia in China, 2019. N Engl J Med 2020 ; 382(8): 727-33.
390	7.	Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
391		Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a
392		Report of 72314 Cases From the Chinese Center for Disease Control and
393		Prevention. JAMA 2020 .
394	8.	Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of
395		COVID-19. JAMA 2020 .
396	9.	Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a
397	10	new coronavirus of probable bat origin. Nature 2020 .
398	10.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
399		novel coronavirus in Wuhan, China. Lancet 2020 ; 395(10223): 497-506.
400	11.	Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated
401		with the 2019 novel coronavirus indicating person-to-person transmission: a
402	10	study of a family cluster. Lancet 2020 ; 395(10223): 514-23.
403 404	12.	Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with
404		acute respiratory distress syndrome. Lancet Respir Med 2020 .

405 406 407	13.	Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003 ; 326(7403): 1358-62.
408	14.	Lau SK, Lau CC, Chan KH, et al. Delayed induction of proinflammatory
409		cytokines and suppression of innate antiviral response by the novel Middle
410		East respiratory syndrome coronavirus: implications for pathogenesis and
411		treatment. J Gen Virol 2013 ; 94(Pt 12): 2679-90.
412	15.	Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the
413		pathology and pathogenesis of the emerging human pathogenic
414		coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol 2020 .
415	16.	Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical
416		transmission potential of COVID-19 infection in nine pregnant women: a
417 418	17.	retrospective review of medical records. The Lancet 2020 . To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel
410	17.	coronavirus in saliva. Clin Infect Dis 2020 .
420	18.	Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory
421	10.	virus infection: balancing virus clearance and immunopathology. Semin
422		Immunopathol 2016 ; 38(4): 471-82.
423	19.	Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe
424		acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent
425		BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J
426		Virol 2010 ; 84(3): 1289-301.
427	20.	Janice Oh HL, Ken-En Gan S, Bertoletti A, Tan YJ. Understanding the T cell
428		immune response in SARS coronavirus infection. Emerg Microbes Infect 2012 ;
429		1(9): e23.
430	21.	Zhao J, Zhao J, Perlman S. T cell responses are required for protection from
431		clinical disease and for virus clearance in severe acute respiratory syndrome
432	22	coronavirus-infected mice. J Virol 2010 ; 84(18): 9318-25.
433	22.	Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles
434 435		of severe acute respiratory syndrome. Am J Respir Crit Care Med 2005 ;
435 436	23.	171(8): 850-7. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral
437	23.	shedding and immunological responses in MERS patients representing a
438		broad spectrum of disease severity. Sci Rep 2016 ; 6: 25359.
439	24.	Sadighi Akha AA. Aging and the immune system: An overview. J Immunol
440	-	Methods 2018 ; 463: 21-6.
441	25.	Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment
442		effects. PLoS Med 2006 ; 3(9): e343.
443	26.	Olnes MJ, Kotliarov Y, Biancotto A, et al. Effects of Systemically Administered
444		Hydrocortisone on the Human Immunome. Sci Rep 2016 ; 6: 23002.
445	27.	Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human
446		respiratory disease in China. Nature 2020 .
447	28.	Li T, Qiu Z, Zhang L, et al. Significant changes of peripheral T lymphocyte
448		subsets in patients with severe acute respiratory syndrome. J Infect Dis 2004 ;
449	20	189(4): 648-51.
450	29.	Okada H, Kobune F, Sato TA, et al. Extensive lymphopenia due to apoptosis
451 452		of uninfected lymphocytes in acute measles patients. Arch Virol 2000 ; 145(5):
452 453	30.	905-20. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. Pathogenesis of
455 454	50.	avian influenza A (H5N1) viruses in ferrets. J Virol 2002 ; 76(9): 4420-9.

455 456 457	31.	Bautista EM, Ferman GS, Golde WT. Induction of lymphopenia and inhibition of T cell function during acute infection of swine with foot and mouth disease virus (FMDV). Vet Immunol Immunopathol 2003 ; 92(1-2): 61-73.
458	32.	O'Donnell DR, Carrington D. Peripheral blood lymphopenia and neutrophilia in
459		children with severe respiratory syncytial virus disease. Pediatr Pulmonol
460		2002 ; 34(2): 128-30.
461	33.	Li CX, Li YY, He LP, et al. The predictive role of CD4(+) cell count and
462		CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients
463		receiving antiretroviral therapy: an eight-year observation in China. BMC
464		Immunol 2019 ; 20(1): 31.
465	34.	He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome
466		(SARS) coronavirus infection on peripheral blood lymphocytes and their
467		subsets. Int J Infect Dis 2005 ; 9(6): 323-30.
468	35.	Yang Y, Xiong Z, Zhang S, et al. Bcl-xL inhibits T-cell apoptosis induced by
469		expression of SARS coronavirus E protein in the absence of growth factors.
470		Biochem J 2005 ; 392(Pt 1): 135-43.
471	36.	Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome
472		Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine
473		Development. J Immunol Res 2019 ; 2019: 6491738.

Table 1. Demographics, baseline characteristics, treatment, and clinical

	Total	Viral clearance	without viral	P value
	(n=25)	(n=14) ^a	clearance	
			(n=11) ^a	
Sex				
female	14(56.0%)	9(64.3%)	5(45.5%)	0.435
male	11(44.0%)	5(35.7%)	6(54.5%)	
Huanan Seafood Wholesale	14 (56.0%)	9 (64.3%)	5 (45.5%)	0.697
Market or patient infected with				
SARS-CoV-2 exposure				
Age, mean ±SD, y	51.4 ± 11.6	44.5 ± 13.0	60.2 ± 16.9	0.015
Comorbidities				
Hypertension	3(12.0%)	0(0.0%)	3(25.0%)	0.072
Cardiovascular disease	2(8.0%)	1(7.0%)	1(9.1%)	1.000
Diabetes	2(8.0%)	0(0.0%)	2(18.2%)	0.183
Malignancy	1(4.0%)	0(0.0%)	1(9.1%)	0.440
COPD	0(0.0%)	0(0.0%)	0(0.0%)	-
Chronic liver disease	3(12.0%)	0(0.0%)	3(25.0%)	0.072
Signs and symptoms				
Fever	18 (75.0%)	8 (57.1%)	10 (90.9%)	0.090
Fatigue	20 (80.0%)	11 (78.6%)	9 (81.8%)	1.000
Myalgia	17 (68.0%)	8 (57.1%)	9 (81.8%)	0.234
Cough	16 (64.0%)	9 (64.3%)	5 (45.5%)	0.697
Dyspnea	7 (28.0%)	4 (28.6%)	3 (27.3%)	1.000
Diarrhea	5 (20.0%)	2 (14.3%)	3 (27.3%)	0.623

477 outcomes of 25 patients infected with SARS-CoV-2

Headache	2 (8.0%)	0 (0.0%)	2 (13.3%)	0.183
Heart rate, mean ±SD, bpm	88.2±15.1	86.8±11.8	89.9 ± 18.9	0.617
Respiratory rate, median (IQR)	20.0 (19.0, 22.0)	20.0 (19.0, 22.0)	20.0 (19.0, 22.0)	0.845
Mean systolic blood pressure,	130.0 ± 24.4	126.8 ± 22.6	134.2 ± 27.1	0.464
mean ±SD, mm Hg				
Days from illness onset to	6 (3,11)	8 (3,11)	6 (3,11)	1.000
hospital, median (IQR), d				
Hospital stays, median (IQR), d	17.0 (11.5, 21.5)	12.0 (10.0,15.0)	21.0 (18.0,23.0)	0.001
Treatment				
Oxygen support	15 (60%)	6 (42.9%)	9 (81.8%)	0.099
Antiviral therapy	24(96.0%)	13(92.9%)	11(100.0%)	1.000
Antibiotic therapy	25(100.0%)	14(100.0%)	11(100.0%)	-
Use of corticosteroid	14 (56.0%)	6(42.9%)	8(72.7%)	0.227
Clinical outcome ^b				
Remained in hospital	9(36.0%)	2(14.3%)	7(63.6%)	0.017
Discharged	16(64.0%)	12(85.7%)	4(36.4%)	

479 ^a After 7-14 days, viral clearance or not was determined by viral RNA detections.

480 ^b After 18-25 days, patients were discharged according to the guideline: 1) a series negative result of

⁴⁸¹ viral RNA detection; 2) no clinical symptoms; 3) improved chest CT imaging.

Table 2. Laboratory results of 25 patients with the outcome of viral

clearance.

	Normal	Total	Viral clearance(n=14)	without viral	P value
	Range			clearance (n=11)	
White blood cell Count ($\times 10^9$ /L)	3.5-9.5	4.5±1.9	4.5±1.7	4.5±2.2	0.919
Lymphocyte count (×10 ⁹ /L)	1.1-3.2	0.9 (0.6, 1.3)	0.8 (0.6, 1.4)	0.9 (0.6, 1.2)	0.565
Monocyte count (×10 ⁹ /L)	0.1-0.6	0.37±0.15	0.33±0.15	0.42±0.14	0.117
Neutrophil count (×10 ⁹ /L)	1.8-6.3	2.8 (1.5, 4.5)	3.1 (1.6, 4.8)	2.6 (1.3, 4.3)	0.805
Platelet count (×10 ⁹ /L)	125-350	179.5±68.8	191.5±70.4	164.3±66.7	0.336
Alanine aminotransferase (U/L)	9-50	24 (20.5, 38.5)	21 (19, 50.5)	25 (21.0, 35.0)	0.583
Aspartate aminotransferase (U/L)	15-40	26 (21.0, 33.0)	23.0(17.0, 34.8)	28.0(26.0,33.0)	0.066
Total bilirubin (mmol/L)	5-21	9.6 (8.0, 12.7)	9.6 (7.6, 12.2)	10.7 (8.2, 16.7)	0.511
Lactate dehydrogenase (U/L)	125-243	197(164.5, 286.5)	197.0(155.0, 340.0)	201.0(174.0, 279.0)	0.956
Prothrombin time (s)	9.4-12.5	12.3 (11.7, 13.0)	12.6 (11.7,13.5)	12.3 (12.1,12.4)	0.641
Activated partial thromboplastin time (s)	25.1-36.5	29.9±3.0	29.8±2.6	30.0±3.6	0.860
D-dimer, (mg/L)	0-500	187.0 (125.0,309.5)	181.0 (104.5,271.0)	233.0 (145.0,630.0)	0.179
Creatinine (µmol/L)	64-104	65.5±14.6	64.3±14.3	67.0±15.6	0.659
Procalcitonin, ng/mL ≥0.05, No. (%)	< 0.05	5 (20.0%)	3 (21.4%)	2 (18.2%)	1.000
Interleukin-6 (pg/ml)	0-7	16.1 (3.7, 31.4)	13.8 (5.3, 30.2)	17.6 (2.8, 49.9)	0.805
CD3+ T cell count (×10 ⁹ /L)	805-4459	561.0 (338.0, 770.0)	639.0 (400.3, 1038.0)	485.0 (384.0, 732.0)	0.311
CD4+ T cell count (×10 ⁹ /L)	345-2350	297.0 (171.5, 447.5)	327.0 (182.8, 560.5)	220.0 (148.0, 420.0)	0.262
CD8+ T cell count (×10 ⁹ /L)	345-2350	272.9±129.7	291.4±149.3	249.5±101.6	0.435
B cell count (×10 ⁹ /L)	240-1317	111.5±75.8	133.2±84.8	83.8±54.2	0.107
NK cell count (×10 ⁹ /L)	210-1514	170.0 (67.5, 245.0)	193.5 (75.0, 286.0)	170.0 (43.0, 215.0)	0.511

492 **Figure legends**

493 Figure 1. Comparison of peripheral changes in CD3+, CD4+, CD8+ T, 494 B, and NK cell counts in patients who were negative for the SARS-CoV-2 (A-E) and positive (F-J) after 8-14 days of treatment. The medium 495 496 number of peripheral lymphocyte counts are represented in the solid line. 497 The threshold of normal peripheral lymphocyte counts is represented in the dash line. NS means no significant difference tested in statistical 498 analysis: Mann-Whitney U test was used for A, B, E, F since these data 499 500 are non-normal distributed and t-test was used for the other normal 501 distributed data).

502

503	Figure 2. Comparison of peripheral changes in CD3+, CD4+, CD8+ T,
504	B, and NK cell counts in six patients who were negative for the SARS-
505	CoV-2 (A-E) and four patients who were positive (F-J) after 15-23 days
506	of treatment. The medium number of peripheral lymphocyte counts are
507	represented in the solid line. The threshold of normal peripheral
508	lymphocyte counts is represented in the dash line. NS means no
509	significant difference tested in statistical analysis and all data used Mann-
510	Whitney U test.









